Eli Lilly and Company $LLY is Bristol Gate Capital Partners Inc.’s 2nd Largest Position

Bristol Gate Capital Partners Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 14.1% in the fourth quarter, HoldingsChannel reports. The firm owned 80,578 shares of the company’s stock after selling 13,262 shares during the period. Eli Lilly and Company makes up about 5.0% of Bristol Gate Capital Partners Inc.’s portfolio, making the stock its 2nd biggest holding. Bristol Gate Capital Partners Inc.’s holdings in Eli Lilly and Company were worth $86,598,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC grew its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares during the period. 10Elms LLP grew its stake in Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. grew its stake in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the period. Finally, Miller Global Investments LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $33,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Leerink Partners lowered their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a research note on Monday, April 27th. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their target price for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 10th. The Goldman Sachs Group reissued a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday. Finally, CICC Research lifted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,220.37.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,066.59 on Friday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.00 trillion, a price-to-earnings ratio of 37.89, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48. The company has a 50-day moving average price of $942.87 and a two-hundred day moving average price of $1,003.77.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts forecast that Eli Lilly and Company will post 35.82 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Goldman Sachs reaffirmed its Buy rating on LLY and raised its price target to $1,283, signaling confidence in further upside. MarketScreener Latest Ratings
• Positive Sentiment: Jefferies lifted its price target on Eli Lilly to $1,330, also implying meaningful upside from recent trading levels. MarketScreener
• Positive Sentiment: New clinical updates across Lilly’s pipeline, including positive obesity conference data, Alzheimer’s study progress, and a new heart-failure trial, help reinforce the market’s view that Lilly has multiple growth drivers beyond its current diabetes and obesity drugs.
• Neutral Sentiment: Lilly also announced an acquisition of Engage Biologics, extending its gene-therapy ambitions; this supports long-term diversification, but the near-term stock impact is less direct. Eli Lilly’s Engage Biologics Deal Extends Genetic Bets Beyond Obesity Boom

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.